SBI Securities Co., Ltd.
Broker-DealerPosition in APLS — Apellis Pharmaceuticals, Inc.
CIK 1851815
TOKYO, M0
Position in APLS
as of Mar 31, 2026
· filed Apr 28, 2026
Position Value
$0
+$0 QoQ
Shares Held
257
+87.6% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in APLS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026SBI Securities Co., Ltd. holds $14,018,008 across 419 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RPRX |
Royalty Pharma plc
|
37,489 | $2,102,008 | |
| 2 | IBRX |
ImmunityBio, Inc.
|
136,321 | $1,193,490 | |
| 3 | MRNA |
Moderna, Inc.
|
16,425 | $1,150,242 | |
| 4 | VKTX |
Viking Therapeutics, Inc.
|
28,729 | $1,120,718 | |
| 5 | GYRE |
Gyre Therapeutics, Inc.
|
166,750 | $1,098,882 | |
| 6 | ABSI |
Absci Corp
|
67,956 | $787,610 | |
| 7 | RXRX |
Recursion Pharmaceuticals, Inc.
|
204,333 | $749,902 | |
| 8 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,270 | $630,847 |
All Filings in APLS
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | — | 257 | Shares | Defined | 2026-04-28 | |
| 2025-12-31 | — | 137 | Shares | Defined | 2026-02-03 | |
| 2025-09-30 | — | 93 | Shares | Defined | 2025-11-05 | |
| 2025-06-30 | — | 91 | Shares | Defined | 2025-08-08 | |
| 2025-03-31 | — | 89 | Shares | Defined | 2025-05-02 | |
| 2024-12-31 | — | 85 | Shares | Defined | 2025-02-06 | |
| No filing history on record for this holder in this stock. | ||||||